China’s HER2-targeted ADC Trastuzumab Rezetecan gains NMPA approval for HER2-mutant NSCLC

Experimental Drug Development Centre granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to...

Blenrep (belantamab mafodotin) combinations receive positive CHMP opinion in relapsed/refractory multiple myeloma

Patritumab Deruxtecan biologics license application (BLA) for patients with previously treated locally advanced or metastatic...

ASCENT-03: Trodelvy demonstrates highly statistically significant & clinically meaningful improvement in progression free survival in...

Astellas enters exclusive license agreement with Evopoint Biosciences for XNW27011, a novel clinical-stage ADC Targeting...